The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...
AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $207.67 billion and ...
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...
Bengals head coach Zac Taylor said after the game that Brown suffered an ankle sprain. "And Brown has been absolutely huge for this offense," NFL Network play-by-play announcer Kevin Harlan said ...
The FDA has approved Calquence (acalabrutinib) for use in combination with bendamustine and rituximab to treat adults with previously untreated MCL who are ineligible for transplant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback